Cullinan Therapeutics, Inc. announced updated Phase 1 OUTRACE clinical trial data for CLN-978 in patients with rheumatoid arthritis and systemic lupus erythematosus. In the rheumatoid arthritis cohort, a patient achieved DAS28-ESR remission at week eight. The company also shared initial Phase 1b/2a data for velinotamig in China, where two patients achieved complete renal response and significant reductions in SLEDAI-2K scores. Cullinan Therapeutics, Inc. is a biotechnology company focused on developing immunology-related therapies.

Cullinan Therapeutics, Inc. announced initial Phase 1 OUTRACE clinical trial data for CLN-978 in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The data showed significant B cell depletion and improvements in disease activity markers for both conditions, though a single case of Grade 3 cytokine release syndrome (CRS) was reported in the 45 <mu>g target dose cohort.